Dual pathway inhibition demonstrated real-world clinical benefits consistent with randomized trial data among high-risk patients with diabetes mellitus and cardiovascular disease.
Does dual pathway inhibition improve outcomes in patients with diabetes mellitus and cardiovascular disease or peripheral artery disease?
Real-world data from the XATOA registry supports the benefit of dual pathway inhibition in high-risk patients with diabetes and cardiovascular or peripheral artery disease.
Absolute Event Rate: 0% vs 0%
Patients with DM with CVD are at significantly high cardiovascular risk, and those with PAD appear to be undertreated. Real-world outcomes observed in the XATOA registry are consistent with randomized trial data, supporting the benefit of DPI in this high-risk population.
Salle et al. (Mon,) reported a other. Dual pathway inhibition demonstrated real-world clinical benefits consistent with randomized trial data among high-risk patients with diabetes mellitus and cardiovascular disease.